Ocriplasmin

Class: EENT Drugs, Miscellaneous
VA Class: OP900
Chemical Name: Micro-(synthetic human) plasmin
Molecular Formula: C₁₂₁₄H₁₈₉₀N₃₃₈O₃₄₈S₁₄
CAS Number: 1048016-09-6
Brands: Jetrea

Medically reviewed by Drugs.com on Aug 25, 2021. Written by ASHP.

Introduction

Recombinant truncated form of human plasmin (a serine protease); a vitreolytic agent.

Uses for Ocriplasmin

Vitreomacular Adhesion

Treatment of symptomatic vitreomacular adhesion (VMA).

Provides pharmacologic (nonsurgical) option for patients with less severe symptomatic VMA to receive treatment at an earlier stage and potentially avoid surgical complications.

Ocriplasmin Dosage and Administration

Administration

Ophthalmic Administration

Administer by intravitreal injection only into the affected eye by a qualified physician.

Must be diluted prior to intravitreal administration. Remove vial from freezer and allow contents to thaw at room temperature for several minutes. Once completely thawed, dilute with 0.2 mL of sterile, preservative-free 0.9% sodium chloride for injection. Gently swirl to mix contents.

Prior to intravitreal administration, withdraw entire contents of vial (0.4 mL) through a sterile 19-gauge needle into a 1-mL syringe (both provided by manufacturer ) using aseptic technique. Discard needle and replace with sterile 30-gauge needle (also provided by manufacturer ) for intravitreal injection. To obtain appropriate dose (0.125 mg), carefully expel air bubbles and excess drug until plunger tip is aligned with the line that marks 0.1 mL on the syringe. Use immediately because drug product contains no preservatives.

Inject under controlled aseptic conditions (including use of sterile gloves, sterile drape, and sterile eyelid speculum [or equivalent]) following adequate anesthesia and administration of a broad-spectrum anti-infective agent.

To administer intravitreally, insert 30-gauge injection needle 3.5–4 mm posterior to the limbus, aiming toward the center of vitreous cavity in order to deliver intended dose to the mid-vitreous. Avoid injecting into the horizontal meridian.

Monitor patients for elevation of IOP immediately following intravitreal injection; monitoring may include evaluation of optic nerve head perfusion or tonometry. A sterile paracentesis needle should be available.

Use each vial only for treatment of a single eye; discard any unused portion. If contralateral eye requires treatment, use a new vial; change sterile field, syringe, gloves, drape, eyelid speculum, and injection needle before administering into the other eye. (See Dosage under Dosage and Administration.)

Repeated administration in the same eye is not recommended.

Dosage

Adults

Symptomatic Vitreomacular Adhesion

Ophthalmic Administration

Intravitreal injection: 0.125 mg (0.1 mL of diluted solution) into the affected eye once as a single dose. Repeated doses not recommended because of possible increased risk of lens subluxation. (See Lens Subluxation under Cautions....